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Abstract
Participant-level meta-analyses assessed the age-specific relevance of office blood pressure to 
cardiovascular complications, but this information is lacking for out-of-office blood pressure. At 
baseline, daytime ambulatory (n=12,624) or home (n=5297) blood pressure were measured in 
17,921 participants (51.3% women; mean age, 54.2 years) from 17 population cohorts. 
Subsequently, mortality and cardiovascular events were recorded. Using multivariable Cox 
regression, floating absolute risk was computed across four age bands (≤60, 61–70, 71–80 and >80 
years). Over 236,491 person-years, 3855 people died and 2942 cardiovascular events occurred. 
From levels as low as 110/65 mm Hg, risk log-linearly increased with higher out-of-office systolic/
diastolic blood pressure. From the youngest to the oldest age group, rates expressed per 1000 
person-years increased (P<0.001) from 4.4 (95% confidence interval, 4.0–4.7) to 86.3 (76.1–96.5) 
for all-cause mortality and from 4.1 (3.9–4.6) to 59.8 (51.0–68.7) for cardiovascular events, 
whereas hazard ratios per 20-mm Hg increment in systolic out-of-office blood pressure decreased 
(P≤0.0033) from 1.42 (1.19–1.69) to 1.09 (1.05–1.12) and from 1.70 (1.51–1.92) to 1.12 (1.07–
1.17), respectively. These age-related trends were similar for out-of-office diastolic pressure and 
were generally consistent in both sexes and across ethnicities. In conclusion, adverse outcomes 
were directly associated with out-of-office blood pressure in adults. At young age, the absolute 
risk associated with out-of-office blood pressure was low, but relative risk high, whereas with 
advancing age relative risk decreased and absolute risk increased. These observations highlight the 
need of a lifecourse approach for the management of hypertension.
Graphical Abstract
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Introduction
High blood pressure (BP) is the major driver of cardiovascular complications.1–3 Several 
studies established that out-of-office BP, measured by ambulatory4,5 or home6 monitoring is 
a better predictor of mortality and cardiovascular complications than office BP is. The 2017 
American College of Cardiology (ACC)/American Heart Association (AHA) guideline for 
the management of hypertension7 and other directives8,9 recommended that for the proper 
diagnosis and management of hypertension out-of-office BP measurement is a prerequisite. 
To evaluate the prognostic accuracy of out-of-office BP measurement, our consortium set up 
the International Databases on Ambulatory (IDACO)10 and Home (IDHOCO)11 BP in 
Relation to Cardiovascular Outcome. This resource is a powerful instrument to assess the 
relevance of out-of-office BP in a wide array of circumstances, as previously done for office 
BP as predictor of cardiovascular mortality and morbidity.1–3 To our knowledge, a similar 
analysis has never been undertaken for out-of-office BP, including both ambulatory and 
home BP. Hence, by combining individual participant data from longitudinal population 
studies, the objective of the present meta-analysis was to characterize the age- sex- and 
ethnicity-specific relevance of out-of-office BP to the subsequent incidence of mortality and 
fatal and nonfatal cardiovascular events.
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The data that support the findings of this study are available from the corresponding author 
upon reasonable request.
Study Participants
All cohort studies complied with the Declaration of Helsinki for research in humans,12 
received ethical approval from the competent Institutional Review Boards, and included 
randomly recruited participants from populations or communities. All participants provided 
informed written consent. Cohort studies qualified for inclusion, if information on office and 
out-of-office BP and cardiovascular risk factors was available at baseline, if follow-up 
included both fatal and nonfatal events, and if study reports had been published in peer-
reviewed articles.10,11 The online-only Supplementary Appendix, available with the full text 
of this article at http://hyper.ahajournals.org provides further cohort-specific information on 
the catchment areas, sampling strategies, recruitment, participation rate, and the number of 
participants enrolled and analyzed, separately for IDACO (Table S1) and IDHOCO (Table 
S2).
The IDACO database included 13,654 participants from 13 cohort studies,13–22 who had 
their ambulatory BP measured (Figure 1). IDHOCO involved 7571 participants from seven 
studies,6,17,23–25 who had measured their home BP (Figure 1). We excluded participants 
from analysis, if they were younger than 18 years (n=314), if their in-office BP had not been 
measured (n=504), or if they had fewer than 10 daytime ambulatory BP readings (n=176) or 
fewer than two home BP measurements (n=18). We also excluded 702 Ohasama participants 
with incomplete identification, precluding an error-free merging of IDACO and IDHOCO 
data. In 1590 participants, who underwent both ambulatory and home BP monitoring, we 
used daytime ambulatory BP as out-of-office BP. Finally, four data sets were available for 
the statistical analysis (Figure 1): group A consisted of 17,921 participants whose out-of-
office BP was based on their daytime ambulatory BP (n=12,624) or on their self-measured 
home BP (n=5297); group B included 12,624 participants with daytime ambulatory BP; 
group C included 6887 participants with home BP; and group D 10,864 participants, who in 
addition to at least 10 daytime BP readings also had 5 or more nighttime ambulatory BP 
readings, allowing an analysis of the 24-h and nighttime BP (Figure 1).
Blood Pressure Measurement
Portable monitors were programmed to obtain ambulatory BP readings at 30-minute 
intervals throughout the whole day,14,21 or at intervals ranging from 1513 to 3016 minutes 
during daytime and from 3013 to 6016 minutes at night (Table S3). The same macros written 
in Statistical Analysis System (SAS) code processed all ambulatory and home BP 
recordings. While accounting for the daily activities of the participants documented by 
diaries in 64.1% of IDACO participants26 and as consistently done in all IDACO articles 
published since 2007,4 we defined daytime as the interval from 10:00 h to 20:00 h in 
Europeans and South Americans, and from 08:00 h to 18:00 h in Asians. The corresponding 
nighttime intervals ranged from midnight to 06:00 h and from 22:00 h to 04:00 h, 
respectively. Within individual subjects, we weighted the means of the ambulatory BP by the 
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time interval between readings. This gives a weight to each individual BP readings in a 
recording proportional to the preceding time interval.27 Participants measured their home BP 
after 5 minutes of rest in the sitting position over periods ranging from a single day17 up to 
30 days25 (Table S4). All devices used for ambulatory (Table S3) or home (Table S4) BP 
measurement had passed validation, using established protocols, and were fitted to an upper-
arm cuff with an appropriate size for each participant’s arm circumference.
Ascertainment of Events
We ascertained vital status and the incidence of fatal and nonfatal diseases from the 
appropriate sources in each country, as described in previous IDACO10 and IDHOCO11 
publications. Outcomes were coded according to various versions of the International 
Classification of Diseases. Events of major interest were total mortality and a composite 
cardiovascular outcome consisting of cardiovascular mortality combined with nonfatal 
coronary events, heart failure and stroke. Other events were cardiovascular mortality (ICD8 
390–448, ICD9 390.0–459.9, and ICD10 I00–I79 and R96), coronary events (death from 
ischemic heart disease [ICD8 411–412, ICD9 411 and 414, and ICD10 I20, I24–I25], 
sudden death [ICD8 427.2 and 795, ICD9 427.5 and 798, and ICD10 I46 and R96], nonfatal 
myocardial infarction [ICD8/9 410 and ICD10 I21–I22], and coronary revascularization), 
and stroke (ICD8/9 430–434 and 436, ICD10 I60–I64 and I67–I68), not including transient 
ischemic attack. Heart failure (ICD8 428, 427.0, 427.1, 427.2, 429, 5191, and 78214, ICD9 
429, and ICD10 I50 and J81) was included in the composite cardiovascular endpoint. Its 
diagnosis required hospitalization in the Scandinavian cohorts.13,16 In the other cohorts, 
heart failure was either a clinical diagnosis or the diagnosis on the death certificate. All 
events were validated against hospital files or medical records held by primary care 
physicians or specialists. In all outcome analyses, we only considered the first endpoint 
within each category. No participant was lost to follow-up.
Statistical Analysis
For database management and statistical analysis, we used the SAS system, version 9.4, 
maintenance level 5 (SAS Institute Inc., Cary, NC). Means were compared using the large-
sample z-test and proportions by Fisher’s exact test. We computed the 95% confidence 
intervals (CI) of rates as R ± 1.96 × √(R/T), where R and T are the rate and the denominator 
used to calculate the rate.
Information on serum cholesterol level was not available for the Didima cohort24 and was, 
as in previous publications,28 extrapolated from data stratified by sex and 10-year age bands 
from the ATTICA population study,29 which took place at the same time and in the same 
geographical area as the Didima study. Furthermore, after stratification for cohort and sex, 
we interpolated missing values of body mass index (n=310) and serum cholesterol (n=942) 
from the regression slopes on age. In participants with unknown status for smoking (n=205), 
drinking (n=2024), antihypertensive treatment (n=39), diabetes mellitus (n=4) or history of 
cardiovascular disease (n=2), we set the design variable to the cohort- and sex-specific mean 
of the codes (0, 1).
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We determined hazard ratios from Cox models stratified by cohort, using the strata option 
implemented in the PHREG procedure of the SAS software, and adjusted for sex, age, body 
mass index, serum cholesterol, smoking and drinking, antihypertensive drug treatment and 
history of diabetes mellitus and cardiovascular disease. While stratifying for cohort, we 
pooled participants recruited in the framework of the European Project on Genes in 
Hypertension (Novosibirsk, Kraków, Gdańsk, Pilsen and Padova).20 Taking into account the 
incidence of events over the age and BP ranges, we considered four age groups (≤60, 61–70, 
71–80 and >80 years) and five BP categories. For daytime, home and 24-h ambulatory BP, 
the categories were <120, 120–129, 130–139, 140–149 and ≥150 mm Hg systolic and <70, 
70–74, 75–79, 80–84 and ≥85 mm Hg diastolic. For the nighttime ambulatory BP, the 
categories were <110, 110–119, 120–129, 130–139 and ≥140 mm Hg systolic and <60, 60–
64, 65–69, 70–74 and ≥75 mm Hg diastolic. For analysis of systolic and diastolic BP, this 
yielded each time 20 groups, of which the youngest with the lowest BP was taken as 
reference with a hazard ratio of 1.0. Relative to this, the 19 other hazard ratios associated 
with BP were estimated simultaneously by Cox regression. This approach allows assigning 
an error term to each hazard ratio, including that of the reference group and avoids any 
assumption to be made as to whether the proportional risks associated with BP differ 
according to age group. Collectively, the 20 hazard ratios are all related to the absolute event 
rate in the study population by some common constant of proportionality and were presented 
as floating absolute risks.30 We checked the proportional hazards assumption and the 
functional forms of the covariables by the Kolmogorov-type supremum test. We applied the 
Lexis expansion31 for age in Cox regression, which converts one observation per subject 
(age at entry) into several observations of different age-at-risk bands. This approach allows 
adjusting for attained age at risk rather than for age at entry. We compared hazard ratios 
between sexes and ethnic groups, using a normal approximation of the log-transformed point 
estimates and standard errors. Finally, using Cox regression, we expressed the risks of 
adverse health outcomes associated with BP for 20 mm Hg and 10 mm Hg increments in 
systolic and diastolic BP, respectively.
Results
Baseline Characteristics
Of 17,921 participants, 12,624 had their out-of-office BP assessed by daytime ambulatory 
monitoring and 6887 by self-measurement at home (Table 1). According to ethnicity, 22.2% 
were Chinese (n=880) or Japanese (n=3091), 62.3% were Eastern Europeans (Czech 
Republic, Poland and Russian Federation; n=1082), Western Europeans (Belgium, Greece, 
Ireland and Italy; n=4579) or Scandinavians (Denmark, Finland and Sweden; n=5505), and 
15.5% were South Americans mainly of European ancestry (Argentina, Uruguay and 
Venezuela; n=2784). About half of the study population (51.3%) was female.
In the 17,921 participants with either daytime (n=12,624) or home (n=5297) BP (group A; 
Figure 1), mean systolic/diastolic values were 129.3/78.2 mm Hg for out-of-office BP, 
129.3/78.8 mm Hg for daytime BP, and 129.1/76.9 mm Hg for home BP. Age at enrolment 
ranged from 18 to 97 years. Mean values were 54.2 years for age, 25.6 kg/m2 for body mass 
index, 5.54 mmol/L for serum cholesterol and 5.28 mmol/L for blood glucose. For smoking 
Li et al. Page 8













the prevalence was 25.6%, 46.6% for drinking, and 50.4% for being overweight or obese; 
6.7% of participants had diabetes mellitus and 10.6% a history of cardiovascular disease. 
The characteristics of the cohorts who had their daytime ambulatory BP (n=12,624; group 
B) or home BP (n=6887; group C) measured mirrored those of the overall study population 
(Figure 1 and Table 1). Among 10,864 participants (group D), the 24-h and nighttime BP 
averaged 123.9/74.0 mm Hg and 112.9/65.1 mm Hg, respectively (Figure 1 and Table 1).
Quality of the Blood Pressure Measurements
Among IDACO participants, the median number of ambulatory readings averaged to 
estimate the daytime (group B), nighttime (group D) and 24-h blood pressure (group D) was 
29 (5th-95th percentile interval, 15–41), 11 (6–13) and 56 (35–82), respectively. Similar data 
are given for each IDACO cohort separately in Table S3 for the 24-h BP and in Table S5 for 
the daytime and nighttime BP. In all IDHOCO participants (group C), the median number of 
home BP readings per individual was 28 (2–56). The corresponding data for each IDHOCO 
cohort are available in Table S4.
Incidence of Events
The number of person-years of follow-up totaled 236,491 in 17,921 participants, who had 
either their daytime or home BP measured (group A). Over a median follow-up of 13.2 years 
(5th-95th percentile interval, 3.5–24.2), 3855 deaths occurred, of which 1441 (37.4%) were 
cardiovascular. Of 2942 fatal or nonfatal cardiovascular events, 1303 (44.3%) were due to 
ischemic heart disease and 1174 (39.9%) to stroke. Total and cardiovascular mortality ran at 
rates of 16.3 (CI, 15.8–16.8) and 6.09 (CI, 5.78–6.41) deaths per 1000 person-years, and 
cardiovascular events, coronary events and stroke at rates of 13.1 (CI, 12.6–13.5), 5.61 (CI, 
5.31–5.92) and 5.08 (CI, 4.79–5.37) events per 1000 person-years with similar estimates in 
groups B and C (Table S6).
Age-Specific Risk of Death or Cardiovascular Events
Absolute risk of all events increased across the four age strata (Table 2). Figure 2 shows the 
log-linear associations of total and cardiovascular mortality and fatal and nonfatal 
cardiovascular events with systolic and diastolic out-of-office BP. The five points plotted for 
each age group were well fitted by the age-specific regression lines. In all age groups, there 
was a graded increase in risk with higher category of systolic and diastolic out-of-office BP 
starting from levels below 110 mm Hg systolic and below 65 mm Hg diastolic. This pattern 
was consistent for home (group A), daytime (group B), nighttime (group D) and 24-h (group 
D) systolic (Figure S1) and diastolic (Figure S2) BP. Sensitivity analyses using age at 
baseline instead of age at risk produced confirmatory results for both systolic and diastolic 
BP (Figure S3).
Hazard ratios for 20/10 mm Hg increments in systolic/diastolic BP were computed for total 
mortality and fatal plus nonfatal cardiovascular and coronary events and stroke (Figure 3). 
For all events under study, relative risk as captured by the multivariable-adjusted hazard 
ratios increased with age, irrespective of whether age-at-risk (Lexis expansion applied; 
Figure 3; P≤0.0385) or age at baseline was used (Lexis expansion not applied; Figure S4; 
P≤0.0420). This age-related increase in relative risk was largely persistent, if participants 
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aged ≤60 years were further subdivided into two age bands (51–60 years and ≤50 years, 
Figure S5), if patients with a history of cardiovascular disease (n=1893 [10.6%]) or those on 
antihypertensive drug treatment at baseline (n=3721 [20.8%]) were excluded (Figure S6), or 
if daytime ambulatory and home BPs were analyzed separately (Figure S7). In the 1893 
participants with a history of cardiovascular disease, there was no J-curve in the association 
of total mortality or the composite cardiovascular endpoint with systolic or diastolic out-of-
office BP (Figure S8).
Analyses Stratified by Sex and Ethnicity
Across the four age groups, there were no sex differences (P≥0.2004) in the multivariable-
adjusted hazard ratios relating adverse health outcomes to systolic or diastolic out-of-office 
BP (Figure S9). The study population included 13,950 people of European descent 
(including South American) and 3971 Asians. Across the four age groups, there were few 
ethnic differences (P≥0.1148) in the multivariable-adjusted hazard ratios relating adverse 
health outcomes to systolic or diastolic out-of-office BP (Figure S10). In the age band from 
71 to 80 years (Figure S10), Asians compared with Europeans had a higher risk of 
cardiovascular events in relation to systolic/diastolic out-of-office BP (hazard ratios, 1.57 vs. 
1.22/1.34 vs. 1.11; P≤0.0340). Similarly, in the age band from 61 to 70 years, cardiovascular 
risk was also higher in Asians than in Europeans (1.78 vs. 1.33/1.50 vs. 1.17; P≤0.0310).
Discussion
The incidence of cardiovascular mortality and fatal combined with nonfatal cardiovascular 
complications showed a direct and graded relation with the level of the systolic and diastolic 
out-of-office BP. The risk associated with out-of-office BP log-linearly increased from levels 
lower than 110 mm Hg systolic and 65 mm Hg diastolic without any evidence for a 
threshold. Absolute risk associated with the out-of-office BP increased with age, but relative 
risk showed an opposite trend, generally increasing from the oldest to youngest age group. 
These findings were broadly consistent in women and men and across ethnicities.
The observation that from the oldest to the youngest age group absolute risk associated with 
out-of-office BP decreased, whereas over the same age span relative risk increased, is of 
great clinical relevance. Indeed, the management of hypertension must be viewed from a 
lifecourse perspective.32 Treatment of high BP in young and middle-aged adults prevents 
subclinical target organ damage and progression to major cardiovascular complications and 
therefore affects the lifecourse trajectory more than treatment of older people, who are at 
high absolute risk. With few exceptions, the age-specific risks associated with out-of-office 
BP were largely consistent in women and men and across people of European and Asian 
ancestry. In the age bands from 61 to 70 years and from 71 to 80 years, overall 
cardiovascular risk associated with out-of-office BP was higher in Asians than in Europeans. 
Although findings in subgroups might arise by chance, our observations potentially reflect 
the vast potential for better cardiovascular prevention by antihypertensive treatment in young 
and middle-aged women,33 usually thought to be at lower risk than men as well as the 
possibility of countering the emerging epidemic of coronary artery disease in Asian 
populations, in whom stroke was traditionally the major complication of hypertension.34 In 
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fact, a lifecourse approach should not only be applied to hypertension, but to all established 
modifiable cardiovascular risk factors as well. It should start from childhood and include a 
more vigorous reinforcement of lifestyle recommendations and a comprehensive 
management of risk indicators, over and beyond blood pressure, including but not limited to 
dyslipidemia, impaired glucose tolerance, diabetes mellitus, active and passive exposure to 
tobacco smoke, early or excessive alcohol consumption, and air pollution. Such policies 
must pave the way to patient empowerment and a personalized patient-centered care.
Multiple studies established that out-of-office BP, measured by ambulatory4,5 or home6 
monitoring is a better predictor of adverse health outcomes compared with office BP. In the 
meta-analysis of one million adults, a 20 mmHg lower usual systolic BP was associated with 
more than a twofold difference in vascular mortality at ages 40–49 years, and about one-
third less vascular mortality at ages of 80–89 years.1 In our current analysis, hazard ratios of 
cardiovascular mortality associated with a 20 mmHg increase in out-of-office systolic BP 
were 1.84 at and below 60 years of age and 1.19 above 80 years. Estimates of relative risk 
not only depend on the number of events and person-years accruing during a study, but also 
on the precision with which a risk factor and the outcome under study is measured. In the 
aforementioned meta-analysis published in 2002,1 the authors analyzed incident vascular 
mortality in cohorts recruited from 1949 until 1990 (median 1974; 5th-95th percentile 
interval, 1959–1987). BP was measured, using standard or random-zero 
sphygmomanometers with strong preference in some cohorts for recording levels ending in 
zero; in three studies of US physicians, nurses and health professionals, the participants 
reported their own BP. In the current study, we applied guideline-endorsed out-of-office BP 
monitoring which provides more precise estimates of an individual’s usual BP.7–9 Moreover, 
the increasing deployment of invasive treatment modalities to remediate coronary, 
cerebrovascular and peripheral arterial conditions drastically reduced cardiovascular 
mortality. For instance, in a multi-ethnic Asian cohort of 40,623 stroke cases, the 28-day 
case fatality rate fell by 17.2% from 2006 until 2012.35 Along similar lines, among 77,211 
incident cases of hospitalized acute myocardial infarction followed up in a Scottish study, at 
all ages (55, 65 and 75 years) and in both sexes, the 30-day case-fatality rate approximately 
dropped by approximately 50% from 2006 until 2015.36 These observations possibly explain 
why the hazard ratios of cardiovascular mortality were lower in our than in Lewington’s 
study.1
Diagnostic flow charts for the application of ambulatory and home BP monitoring have been 
published.7–9 Both approaches of out-of-office BP measurement are mature, cost-effective,37 
and can be immediately rolled out on a global scale to clinical practice, thereby affecting the 
lives of millions of people at risk. In low-resource settings, home BP measurement is an 
alternative for ambulatory BP monitoring. Furthermore, out-of-office BP measurement is 
required for the diagnosis of masked hypertension; a condition characterized by normal in-
office, but elevated out-of-office BP. It has a prevalence of approximately 15% in the general 
population, and up to 30% in patients with diabetes mellitus.38 Masked hypertension carries 
a risk similar to that of combined office and out-of-office hypertension.38 Similarly, out-of-
office BP monitoring enables avoiding needless antihypertensive treatment in patients with 
an elevated in-office, but normal out-of-office BP, so called white-coat hypertension.39 In 
individual patients, daytime and home BP may provide different, albeit still complimentary, 
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information. However, an epidemiological study, such as the current report, does not deal 
with the management of individual patients, but with risk assessment. We therefore chose to 
pool daytime and the self-measured home BP as two modalities of out-of-office BP. The 
rationale was that both types of out-of-office BP measurement are obtained during 
wakefulness and have the same guideline-endorsed reference thresholds.7–9 Moreover, the 
pooled analysis of daytime and home BP was consolidated by similar results for the home, 
daytime, nighttime and 24-h BP analyzed separately.
The present study describes for the first time the age- sex- and ethnicity-specific risks 
associated with out-of-office BP. Generalizability is one of its strong points: (i) the available 
database included information on close to 18,000 individuals, spanning the whole adult age 
range with equal representation of women and men; (ii) the participants were randomly 
recruited from populations in 14 countries and three continents; (iii) and the outcomes were 
collected over a median of 13.2 years of follow-up and encompassed both fatal and nonfatal 
outcomes validated against the sources available in each country. To our knowledge, only 
two population studies,40,41 which complied with the selection criteria of IDACO published 
in 2007,10 did not contribute data to the current analysis, because nonfatal events accrued 
only after the IDACO database had been constructed40 or because only aggregate data could 
be made available.41 Notwithstanding these strengths, our study must also be interpreted 
within the context of its limitations. First, in all cohorts BP was measured only at baseline. 
We could therefore not adjust for regression dilution bias.42 Second, enrolment of the 
IDACO (Table S1) and IDHOCO (Table S2) population cohorts included in this participant-
level meta-analysis started before statins became commonplace in cardiovascular prevention. 
We also did not have standardized information on the initiation of non-pharmacological and 
pharmacological cardiovascular preventive measures during follow-up. However, starting 
antihypertensive or lipid-lowering drugs or health-promoting lifestyle interventions during 
follow-up would not enhance but rather weaken the associations of study events with out-of-
office BP and other risk factors, as measured at baseline. Third, stroke is the complication of 
hypertension closest associated with the BP level,34 but we did not have reliable information 
on stroke subtypes. Fourth, all fatal and nonfatal study endpoint were adjudicated against the 
medical records held by doctors and hospitals. However, in view of the different settings of 
the population studies contributing to IDACO10 and IDHOCO,11 the possibility of some 
misclassification bias in the validation of events cannot be entirely excluded. Finally, Asians 
were under-represented among our cohorts and we had no information on Blacks of African 
descent or Blacks born and living in Africa, who generally are more susceptible to the 
complications of hypertension.43 We also classified participants enrolled in South America 
among people of European descent, although there was some degree of indigenous 
admixture, in particular in the Maracaibo Aging Study.22
Perspectives
In this first study of the age- sex- and ethnicity-specific risks of death and cardiovascular 
complications associated with out-of-office BP, at young age, relative risk was high and 
absolute risk low, whereas with advancing age relative risk associated with out-of-office BP 
decreased and absolute risk increased. These observations underscore the need for a 
lifecourse approach to the management of hypertension. They highlight the necessity to start 
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antihypertensive treatment early in young and middle-aged adults for primary prevention, in 
particular in women, who compared with men have the same relative risk. In older people, 
BP lowering treatment should aim at the prevention of disabling complications and 
extending years lived without disability.
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Refer to Web version on PubMed Central for supplementary material.
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In a participant-level meta-analysis, we recorded out-of-office blood pressure (BP), either 
daytime ambulatory (n=12,624) or home (n=5297) BP in 17,921 participants enrolled 
from 17 populations. Subsequently, mortality and cardiovascular events were recorded. 
Using multivariable Cox regression, floating absolute risk was computed across four age 
bands (≤60, 61–70, 71–80 and >80 years) and 5 systolic or 5 diastolic BP categories.
What is relevant?
• Over 236,491 person-years, 3855 people died and 2942 cardiovascular events 
occurred.
• From 110/65 mm Hg, risk log-linearly increased with higher out-of-office 
systolic/diastolic BP.
• From ≤60 to >80 years, rates per 1000 person-years increased from 4.4 to 
86.3 for all-cause mortality and from 4.1 to 59.8 for cardiovascular events.
• From ≤60 to > 80 years, hazard ratios per 20-mm Hg increment in systolic 
out-of-office BP decreased from 1.42 (1.19–1.69) to 1.09 (1.05–1.12) for all-
cause mortality and from 1.70 (1.51–1.92) to 1.12 for cardiovascular events.
• These age-related trends were similar for out-of-office diastolic BP and were 
generally consistent in both sexes and across ethnicities.
Summary
Adverse health outcomes were directly associated with out-of-office BP in adults. At 
young age, absolute risk associated with out-of-office BP was low, but relative risk high, 
whereas with advancing age relative risk decreased and absolute risk increased. These 
observations highlight the need of a lifecourse approach for the management of 
hypertension.
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Abbreviations: IDACO, International Database on Ambulatory Blood Pressure in Relation to 
Cardiovascular Outcome (reference 12); IDHOCO International Database of Home Blood 
Pressure in Relation to Cardiovascular Outcome (reference 13); BP, blood pressure; ABP, 
ambulatory blood pressure. In 1590 participants, who had both daytime and home BP 
measured, daytime BP was analyzed as out-of-office BP. Of 12,624 participants with 
daytime BP, 10,864 had ≥5 nighttime BP readings and were included in the analysis for 24-h 
and nighttime BP.
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Total mortality (A, B) and cardiovascular events (C, D) by by age-at-risk groups and 
categories of out-of-office blood pressure.
Point estimates and 95% confidence intervals for the floating absolute risks were plotted 
along the vertical axis. The size of the squares is proportional to the inverse the variance of 
each hazard ratio. Risk estimates were stratified by cohort and adjusted for sex, body mass 
index, serum cholesterol, smoking and drinking, antihypertensive drug treatment and history 
of diabetes mellitus and cardiovascular disease. The categories plotted along the horizontal 
axis are <120, 120–129, 130–139, 140–149 and ≥150 mm Hg for systolic blood pressure 
(SBP) and <70, 70–74, 75–79, 80–84 and ≥85 mm Hg for the diastolic blood pressure 
(DBP). Log-linear relations were fitted for each age group for out-of-office SBP (A, C), and 
DBP (B, D).
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Hazard ratios for out-of-office blood pressure by four age-at risk groups
The Cox models were stratified by cohort and adjusted for sex, age, body mass index, serum 
cholesterol, smoking and drinking, antihypertensive drug treatment and history of diabetes 
mellitus and cardiovascular disease. Hazard ratios, given for four age groups, express the 
risk associated with increments in out-of-office blood pressure (daytime or home) of 20 mm 
Hg systolic (SBP) or 10 mm Hg diastolic (DBP). Squares representing the point estimates 
have a size proportional to the inverse of the variance. Horizontal lines denote the 95% 
confidence interval. P-Values are for trend across the four age groups.
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